Clinical trials: Thoracic Tumor
Cancer, Solid Tumor
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
This is a multiphase, multicenter study, which includes a Phase 1a open-label, dose escalation monotherapy study of ST-067 given as an SC injection with or without obinutuzumab [Gazyva®] pre-treatment, by IV infusion, and in…
- Conditions
- Cancer, Solid Tumor, Melanoma, Renal Cell Carcinoma
- Trial name
- NCT04787042
- Testing
- ST-067, Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA], pembrolizumab
- Where
- 6 sites in United States
- Volunteers
- 316 people
- Sponsor
- Simcha IL-18, Inc.
Carcinoma, Small Cell
Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma
GSK2879552 is a potent, selective, mechanism-based inactivator of Lysine Specific Demethylase 1 (LSD1)/ CoRepressor for Element-1-Silencing Transcription factor (CoREST) activity.
- Trial name
- NCT02034123
- Testing
- GSK2879552
- Where
- 8 sites in United States, France and 1 more
- Volunteers
- 29 people
- Sponsor
- GlaxoSmithKline
NSCLC Stage IV, KRAS Gene Mutation
Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer
This is a randomized, open-label, multi-center, phase II trial to evaluate the efficacy and safety of SHR-1210 plus apatinib mesylate versus Pemetrexed and Carboplatin in Subjects with KRAS mutant stage IV non-squamous Non-small…
- Conditions
- NSCLC Stage IV, KRAS Gene Mutation, PD-1 Antibody, Chemotherapy Effect
- Trial name
- NCT03777124
- Testing
- SHR-1210, Apatinib, Pemetrexed
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
NSCLC
Safety and Efficacy of NK510 to Treat NSCLC
This study assesses the safety and efficacy of NK510 combined with PD-(L)1 inhibitors for relapsed/refractory advanced NSCLC, with two administration routes: intravenous infusion and intrapleural perfusion for malignant pleural…
- Trial name
- NCT06097962
- Testing
- NK510, Tislelizumab，atezolizumab or sugemalimab, systemic therapy as selected by the investigator
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Base Therapeutics (Shanghai) Co., Ltd.
Cancer, Non Small Cell Lung Cancer
Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel
The primary purpose of this study is to explore the safety and tolerability of AZD0530 in combination with carboplatin and paclitaxel in Japanese patients with non small cell lung cancer and epithelial ovarian cancer.
- Conditions
- Cancer, Non Small Cell Lung Cancer, Epithelial Ovarian Cancer
- Trial name
- NCT01000896
- Testing
- AZD0530, Carboplatin, paclitaxel
- Where
- 2 sites in Japan
- Volunteers
- 27 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer
A Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With Erlotinib
This is a single-arm, open-label, multicenter, international pilot study to evaluate changes that occur in 2-deoxy-2-[18F]fluoro-D-glucose (FDG)- and 3'-deoxy-3'-[18F]fluorothymidine(FLT)-PET (Positron Emission Tomography)…
- Trial name
- NCT00453362
- Testing
- 2-deoxy-2-[18F]fluoro-D-glucose (FDG), 3'-deoxy-3'-[18F]fluorothymidine (FLT), erlotinib HCl
- Volunteers
- 88 people
- Sponsor
- Genentech, Inc.
Lung Cancer
Treatment Patterns, Outcomes and Testing in EGFRm NSCLC Patients With EGFR TKI 1L Across Europe (REFLECT)
Multinational, multi-center medical record review to describe the treatment patterns, clinical outcomes, and EGFR / T790M testing practices in EGFR-mutated advanced NSCLC patients receiving first-line EGFR TKI therapy in Europe.
- Trial name
- REFLECT (NCT04031898)
- Testing
- Non Interventional
- Where
- Bulgaria
- Volunteers
- 896 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer
A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This multicenter, single-arm study will evaluate the efficacy and safety of Atezolizumab in participants with PD-L1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).
- Trial name
- BIRCH (NCT02031458)
- Testing
- Atezolizumab
- Where
- 110 sites in United States, Australia and 17 more
- Volunteers
- 667 people
- Sponsor
- Hoffmann-La Roche
Metastatic Non-Small Cell Lung Cancer, NSCLC
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)
This is a randomized, double-blind, placebo-controlled, global, multicenter, Phase 2 trial evaluating the effect of trilaciclib on overall survival when administered prior to docetaxel in patients with metastatic NSCLC treated in…
- Conditions
- Metastatic Non-Small Cell Lung Cancer, NSCLC, Lung Cancer
- Trial name
- PRESERVE 4 (NCT04863248)
- Testing
- Trilaciclib, Docetaxel
- Where
- 12 sites in United States
- Volunteers
- 10 people
- Sponsor
- G1 Therapeutics, Inc.
Lung Cancer, Small Cell
Active Symptom Control Alone Or In Combination With Oral Topotecan In Patients With Relapsed Resistant Small Cell Lung Cancer
The purpose of this study is to find out if giving oral HYCAMTIN to patients with relapsed small cell lung cancer benefits them.
- Trial name
- NCT00276276
- Testing
- topotecan
- Where
- 17 sites in Bulgaria, Hungary and 4 more
- Volunteers
- 141 people
- Sponsor
- GlaxoSmithKline
Carcinoma, Non-Small Cell Lung, HER2 Negative Breast Neoplasms
A Study of SGN-STNV in Advanced Solid Tumors
This trial will look at a drug called SGN-STNV to find out whether it is safe for patients with solid tumors. It will study SGN-STNV to find out what its side effects are.
- Conditions
- Carcinoma, Non-Small Cell Lung, HER2 Negative Breast Neoplasms, Ovarian Neoplasms, Uterine Cervical Neoplasms
- Trial name
- NCT04665921
- Testing
- SGN-STNV
- Where
- 18 sites in United States, Canada and 4 more
- Volunteers
- 111 people
- Sponsor
- Seagen Inc.
Non-Small-Cell Lung Carcinoma, Colorectal Cancer
A Study to Compare Tissue and Liquid Biopsies in People With Different Types of Cancer
In study, liquid biopsy samples will be obtained from non-small cell lung cancer (NSCLC) including Squamous cell carcinoma, Adenocarcinoma and large cell carcinoma, colorectal carcinoma (CRC) and pancreatic ductal adenocarcinoma…
- Conditions
- Non-Small-Cell Lung Carcinoma, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT05708599
- Testing
- Liquid biopsy
- Where
- Germany
- Volunteers
- 102 people
- Sponsor
- Boehringer Ingelheim
Lung Cancer (Diagnosis)
Robotic Bronchoscopy for Small Lung Nodules Without a Bronchus Sign
The goal of this observational study is to learn about the diagnostic performance and safety of robotic-assisted bronchoscopy using the Ion Endoluminal System in adults with small lung nodules that do not show a bronchus sign on…
- Trial name
- NCT07862816
- Where
- 4 sites in South Korea
- Volunteers
- 151 people
- Sponsor
- Intuitive Surgical
Carcinoma, Non-Small-Cell Lung
A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC) Which Has Spread Out.
The purpose of this study is to learn about lorlatinib for the possible treatment of lung cancer which could not be controlled. This study is seeking participants who: have lung cancer that could not be controlled.
- Trial name
- NCT06678555
- Testing
- Lorlatinib
- Where
- Taiwan
- Volunteers
- 22 people
- Sponsor
- Pfizer
Non-Small Cell Lung Cancer
Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative Gemcitabine-Cisplatin in Early Stages NSCLC
Preoperative chemotherapy is considered to play a role in early stage non small cell lung cancer (NSCLC) .The use of preoperative Cisplatin/Gemcitabine chemotherapy has proven feasible and without excessive morbidity or mortality…
- Trial name
- NCT00191126
- Testing
- gemcitabine, Cisplatin, surgery
- Where
- 37 sites in Belgium, Bosnia and Herzegovina and 13 more
- Volunteers
- 263 people
- Sponsor
- Eli Lilly and Company
Pulmonary Nodules
A Prospective Cohort Study of Chinese Patients With Pulmonary Nodules: Prediction of Lung Cancer Using Noninvasive Biomarkers
The broad goals of this study is to identify changes in genomic landscape during transition from stage 0 to stage 1 lung cancer.
- Trial name
- NCT04462185
- Testing
- A genomic and transcriptomic landscape analysis
- Where
- 6 sites in China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- AnchorDx Medical Co., Ltd.
Small-cell Lung Cancer
Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer
The main objective is to compare ZG006 with Investigator-Selected Chemotherapy on prolonging overall survival (OS).
- Trial name
- NCT07189455
- Testing
- ZG006, Topotecan
- Where
- China
- Volunteers
- 420 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Lung Cancer
BICR in New Therapeutic Lung Cancer Trials
Double reads in blinded independent central reviews (BICRs) are recommended to control the quality of trials but they are prone to discordances.
- Trial name
- NCT05038826
- Where
- France
- Volunteers
- 1,833 people
- Sponsor
- Median Technologies
Carcinoma, Non-Small-Cell Lung
PANORAMA - Real World Molecular Testing, Treatment Patterns, and Clinical Outcomes EGFR Mutation-Positive NSCLC
The objectives of this study are to assess molecular testing, treatment patterns, and associated outcomes among patients with EGFR (Epidermal Growth Factor Receptor) mutation-positive locally advanced or advanced NSCLC (Non-Small…
- Trial name
- PANORAMA (NCT02777658)
- Where
- 73 sites in Germany
- Volunteers
- 169 people
- Sponsor
- AstraZeneca
Solid Tumor
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
This is a first in human (FIH) 2-part study using ACTM-838 in patients with advanced solid tumors resistant to standard of care treatment. Part 1a will evaluate dose escalation and Part 1b will evaluate dose expansion.
- Trial name
- NCT06336148
- Testing
- ACTM-838
- Where
- 5 sites in United States, Australia
- Volunteers
- 10 people
- Sponsor
- Actym Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.